Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Glutarate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.92 |
| ▸ | LMNA | P02545 | 5/20 | 0.77 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.75 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.75 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 4/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.59 |
| ▸ | GABRP | O00591 | 1/20 | 0.59 |
| ▸ | GABRD | O14764 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.59 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutarate SCHEMBL29536271 | 1.00 | SLC22A6 (0.92) | SLC22A6LMNAEGLN1ALKBH5SUCNR1 | |
| Glutarate SCHEMBL28947728 | 0.96 | SLC22A6 (0.85) | SLC22A6LMNAEGLN1ALKBH5SUCNR1 | |
| Adipic Acid SCHEMBL2333828 | 0.96 | LMNA (0.85) | SLC22A6LMNAEGLN1ALKBH5SUCNR1 | |
| Adipic Acid SCHEMBL2480632 | 0.96 | LMNA (0.85) | SLC22A6LMNAEGLN1ALKBH5SUCNR1 | |
| Adipic Acid SCHEMBL10002678 | 0.96 | LMNA (0.85) | SLC22A6LMNAEGLN1ALKBH5SUCNR1 | |
| Glutarate SCHEMBL28811854 | 0.96 | SLC22A6 (0.85) | SLC22A6LMNAEGLN1ALKBH5SUCNR1 | |
| Glutarate SCHEMBL6701735 | 0.96 | — | — | |
| Glutarate SCHEMBL27601182 | 0.96 | SLC22A6 (1.00) | SLC22A6LMNAEGLN1ALKBH5SUCNR1 | |
| Glutarate SCHEMBL7414 | 0.96 | — | — | |
| Glutarate SCHEMBL158774 | 0.96 | SLC22A6 (1.00) | SLC22A6LMNAEGLN1ALKBH5SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114533893-A | Preparation method of polypeptide-conjugated paclitaxel with anti-glioma activity | 天津医科大学总医院 | 2022-05-27 | — | — | CN | claimed |
| CN-103254425-B | End-blocking copolyamide PUR and manufacture method thereof | 上海东睿化学有限公司 | 2016-08-17 | — | — | CN | claimed |
| US-6323271-B1 | FOR PRODUCING CLEAR BEVERAGE CONTAINERS | ARTEVA NORTH AMERICA S.A.R.L. (CH) | 2001-11-27 | — | — | US | claimed |
| WO-2000012606-A9 | BIODEGRADABLE THERMOPLASTIC POLYESTER COMPOSITION WITH IMPROVED WETTABILITY | KIMBERLY CLARK CO (US) | 2000-08-03 | — | — | WO | claimed |
| CN-1044935-A | Make the tris-hydroxymethyl alkane esters of low calorie fat mimetics | NABISCO BRANDS INC (US) | 1990-08-29 | — | — | CN | claimed |
| EP-3169403-B9 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-07-03 | — | — | EP | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4378536-A2 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | Protagonist Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4370537-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | Pep2Tango Therapeutics Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | JANSSEN BIOTECH INC (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240132558-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| EP-0151961-B1 | ULTRAVIOLET RADIATION STABILIZED POLYMER COMPOSITIONS | GENERAL ELECTRIC COMPANY (US) | 1989-12-13 | — | — | EP | disclosed |
| US-4636408-A | PHOTOSTABILITY, HINDERED AMINE | GENERAL ELECTRIC COMPANY (US) | 1987-01-13 | — | — | US | disclosed |
| EP-0151961-A1 | Ultraviolet radiation stabilized polymer compositions | GENERAL ELECTRIC COMPANY (US) | 1985-08-21 | — | — | EP | disclosed |
| EP-0060799-A1 | Diester antioxidants | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1982-09-22 | — | — | EP | disclosed |
| US-RE30810-E | HEAT STABILIZERS FOR POLYMERS | THIOKOL CORPORATION (US) | 1981-12-01 | — | — | US | disclosed |
| EP-0033248-A1 | Magnetic toner and method for developing using same | XEROX CORPORATION (US) | 1981-08-05 | — | — | EP | disclosed |
| US-RE30032-E | POLYMER STABILIZERS | CINCINNATI MILACRON CHEMICALS, INC. (US) | 1979-06-12 | — | — | US | disclosed |
| US-4135009-A | BENZOIC ACID TERMINATED OLIGOESTERS AS MELT FLOW MODIFIERS OF THERMOPLASTIC COATINGS AND POWDERS | ROHM AND HAAS COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199700-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | SLC22A6 1670/4885LMNA 4291/4885EGLN1 2634/4885 |
| US-20240132558-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | SLC22A6 1803/4885LMNA 4161/4885EGLN1 2795/4885 |
| US-20240150405-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | SLC22A6 1803/4885LMNA 4161/4885EGLN1 2795/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | SLC22A6 1803/4885LMNA 4161/4885EGLN1 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.